JPRN-UMIN000023578
Recruiting
未知
ong-term maintenance of anti-tumor immune responses by vaccination with tri-WT1 peptide cancer vaccine WT1 Trio - Long-term anti-tumor immune responses by WT1 Trio
Osaka University Graduate School of Medicine Dept. Cancer Immunotherapy0 sites90 target enrollmentSeptember 10, 2016
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Thymic cancer Thymoma Soft tissue sarcoma Malignant glioma Salivary gland cancer Head and neck mucoepidermoid carcinoma Olfactory neuroblastoma Head and neck mucosal malignant melanoma Ophthalmic malignant melanoma Cancer of the external auditory canal Testicular cancer Cancer of penis Adrenal cancer Malignant mesothelioma Cancer of the small intestine Merkel cell carcinoma Cutaneous lymphoma (Rare cancers listed above)
- Sponsor
- Osaka University Graduate School of Medicine Dept. Cancer Immunotherapy
- Enrollment
- 90
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1 A patient with active infectious disease. 2 A patient who experienced SAE (grade \>\=4\) in the previous clinical trial of WT1 peptide vaccine 3 A patient with severe complication or complications. 4 A patient with severe mental disorder. 5 A patient who participates in any other clinical trial 6 A patient who should not be recruited to the clinical trial as determined by the investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Research to elucidate the anti-tumor immune responses and develop the combination therapy in solid tumorSolid tumorJPRN-UMIN000040280Osaka International Cancer Institute, Research center80
Recruiting
Not Applicable
Comprehensive anti-tumor immunity evaluation system for thoracic malignancies using peripheral blood mononuclear cellthoracic malignanciesJPRN-UMIN000042005Saitama Medical University International Medical Center2,000
Recruiting
Not Applicable
Analysis of anti-tumor immunosuppressive mechanism of dendritic cells in pediatric solid tumorsHealthy volunteersJPRN-UMIN000041339Chiba University30
Active, not recruiting
Not Applicable
Strategic long term, immunologically driven treatment interruptions in previously naive patients starting HAART: a controlled, randomized, multicenter study - (Therapeutic Structured Interruptions Study)HIV INFECTIONMedDRA version: 9.1Level: HLTClassification code 10052740Term: Acquired immunodeficiency syndromesEUCTR2006-002805-30-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)
Not yet recruiting
Not Applicable
Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High-Intensity Focused Ultrasound Histotripsy; the iFOCUS study.cancermalignancy10027655NL-OMON56837niversitair Medisch Centrum Utrecht24